April 7 (Reuters) - Insmed (INSM.O), opens new tab said on Tuesday it ‌would discontinue the development of its treatment for a chronic, inflammatory skin condition, after the drug failed a mid-stage ...

A new study from Monash University reveals that adults with Attention-Deficit/Hyperactivity Disorder (ADHD) experience brief sleep-like brain activity during the day ...

Shield AI's Hivemind AI program piloted Anduril's YFQ-44A uncrewed aircraft for the first time. Hivemind was selected earlier to provide autonomy for the Air Force's drone wingmen. The Air Force ...

Sanofi has backed the $75 million series B of a rhinovirus-focused biotech with a former FDA acting commissioner at the helm. Altesa BioSciences unveiled back in 2022 with $4 million in seed funding ...

As Priovant works toward approval of potential blockbuster brepocitinib as a treatment for dermatomyositis, the North Carolina biotech has presented promising results for the TYK2/JAK1 inhibitor in ...

Pfizer (PFE) announced on Tuesday that a mid-stage trial evaluating a monthly maintenance dosing regimen of its experimental obesity drug indicated that the GLP-1 receptor agonist PF’3944 (MET-097i) ...

The lineup for Turning Point USA's "All-American Halftime Show" is finally here. The show, put on by the conservative organization to compete with Bad Bunny's Super Bowl halftime performance, will ...

Breaking space news, the latest updates on rocket launches, skywatching events and more! You are now subscribed Your newsletter sign-up was successful Want to add more newsletters? Delivered daily ...

DALLAS—As pay TV operators continue to struggle with cord cutting and streaming platforms seeks to retain fickle consumers who regularly cancel subscriptions, a new study from Parks Associates takes a ...

A long-running Swedish study has followed adults for nearly five decades, uncovering when physical decline truly begins. Fitness and strength start slipping around age 35, then worsen gradually with ...